Please wait while the formulary information is being retrieved.
DAURISMO (glasdegib maleate)
- Acute myeloid leukemia
100 mg tablet
- 1 tablet (100 mg) by oral route once daily on days 1 through 28 of a 28 day treatment cycle
25 mg tablet
- 2 tablets (50 mg) by oral route once daily on days 1 through 28 of a 28 day treatment cycle
Acute myeloid leukemia
- 2 tablets (50 mg) by oral route once daily on days 1 through 28 of a 28 day treatment cycle
- 1 tablet (100 mg) by oral route once daily on days 1 through 28 of a 28 day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Chronic heart failure
- Congenital long QT syndrome
- Hypokalemia
- Hypomagnesemia
- Pregnancy
- Prolonged QT interval
Severe
Moderate
- None
DAURISMO (glasdegib maleate)
- Acute myeloid leukemia
- Anemia
- Hemorrhage
- Neutropenic disorder
- Thrombocytopenic disorder
- Anorexia
- Constipation
- Dysgeusia
- Dyspnea
- Edema
- Fatigue
- Musculoskeletal pain
- Nausea
- Skin rash
- Stomatitis
More Frequent
Severe
Less Severe
- Atrial arrhythmia
- Atrial fibrillation
- Bradycardia
- Hyperbilirubinemia
- Hyperkalemia
- Hypokalemia
- Hyponatremia
- Hypophosphatemia
- Kidney disease with reduction in GFR
- Pneumonia
- Prolonged QT interval
- Sinus tachycardia
- Acute abdominal pain
- Alopecia
- Chest pain
- Cough
- Diarrhea
- Dizziness
- Fever
- Headache disorder
- Muscle spasm
- Tooth disorder
- Toothache
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Ventricular arrhythmias
- Ventricular fibrillation
- Ventricular tachycardia
Less Severe
- None
Contraindicated
None
Severe Precaution
Glasdegib
Potential risk of skeletal and growth abnormalities. No safety and efficacy.
- 1 Day – 18 Years
- Potential risk of skeletal and growth abnormalities. No safety and efficacy.
Management or Monitoring Precaution
None
Glasdegib
- Severity Level:
D
- Additional Notes: Potential for embryotoxicity/embryolethality based on mechanism of action.
Contraindicated
Glasdegib
Avoid breastfeeding during and 30 days after tx, serious adverse effects poss
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Avoid breastfeeding during and 30 days after tx, serious adverse effects poss |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Glasdegib is not recommended for use during pregnancy because it may cause serious harm (possibly death) to an unborn baby. Women of childbearing age must have a pregnancy test within 7 days before starting this medication. They should also use reliable forms of birth control while taking glasdegib and for at least 30 days after the last dose.<br /><br /> It is unknown if glasdegib passes into semen. Because of the possible risk of passing the drug to a partner, men (including men who have had a vasectomy) must use condoms during sex with women who are pregnant or of childbearing age, both during treatment with glasdegib and for at least 30 days after the last dose. Men should also not donate sperm during this time. If you or your partner become pregnant or think you may be pregnant, tell your doctor right away.
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool